HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD

Henan Taloph Pharmaceutical Stock Co.,Ltd

600222

CNE0000010L8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 20/05/2024 BST			5-day change	1st Jan Change
5.07 ^CNY	-2.31%		-3.80%	-17.29%

04-25	Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-02	Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on February 2, 2024.	CI

Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback announced on July 15, 2022, has closed with 14,523,100 shares, representing 2.57% for CNY 79.72 million.

July 12, 2023

The company closed its plan on July 13, 2023.

Latest news about Henan Taloph Pharmaceutical Stock Co.,Ltd

Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on February 2, 2024.	04-01	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd announces an Equity Buyback for CNY 60 million worth of its shares.	02-01	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd authorizes a Buyback Plan.	01-31	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Henan Taloph Pharma Receives 41 Million Yuan in Government Grants in Q3	09/10/23	MT
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
Taloph Pharmaceutical Gets Nod to Amend License of Three Products	21/07/23	MT
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	13/07/23	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback announced on July 15, 2022, has closed with 14,523,100 shares, representing 2.57% for CNY 79.72 million.	12/07/23	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	03/07/23	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	06/04/23	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	31/03/23	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	03/01/23	CI
Henan Taloph Pharma Vice Chairman Resigns; Shares Slump 10%	19/12/22	MT
Tailong Health Industry Investment Co., Ltd announced that it expects to receive CNY 220 million in funding from Henan Taloph Pharmaceutical Stock Co.,Ltd	09/11/22	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	10/10/22	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	19/08/22	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd announces an Equity Buyback for CNY 80 million worth of its shares.	14/07/22	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd authorizes a Buyback Plan.	13/07/22	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd(SHSE:600222) added to Shanghai Stock Exchange Composite Index	09/05/22	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd(SHSE:600222) dropped from Shanghai Stock Exchange Composite Index	05/05/22	CI

Chart Henan Taloph Pharmaceutical Stock Co.,Ltd

Duration

Period

Chart Henan Taloph Pharmaceutical Stock Co.,Ltd

More charts

HENANTALOPHPHARMACEUTICALSTOCKCO., LTD is a China-based company principally engaged in the research and development, manufacture and sales of pharmaceuticals. The Company provides oral solutions, transfusion and tablets, which are applied in the treatment of cold, diabetes and virus infection. The Company's main products include Shuanghuanglian oral liquid products, double gold agents, Haberffine tablets and compound Yimu oral solutions, among others. The Company distributes its products mainly within domestic market.

Sector

Pharmaceuticals

Calendar

25/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD	-17.29%	400M
ELI LILLY AND COMPANY	+37.78%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	332B
ABBVIE INC.	+5.14%	291B
ASTRAZENECA PLC	+16.64%	238B
ROCHE HOLDING AG	-4.13%	210B
NOVARTIS AG	+10.63%	209B
AMGEN INC.	+9.32%	169B